{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T07:12:00Z","timestamp":1775286720912,"version":"3.50.1"},"reference-count":47,"publisher":"Wiley","issue":"6B","license":[{"start":{"date-parts":[[2015,10,29]],"date-time":"2015-10-29T00:00:00Z","timestamp":1446076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Photocure ASA"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2016,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      To explore the cost impact on Swedish healthcare of incorporating one instillation of hexaminolevulinate hydrochloride (\n                      <jats:styled-content style=\"fixed-case\">HAL<\/jats:styled-content>\n                      ) blue\u2010light cystoscopy into transurethral resection of bladder tumour (\n                      <jats:styled-content style=\"fixed-case\">TURBT<\/jats:styled-content>\n                      ) in patients with suspected new or recurrent non\u2010muscle\u2010invasive bladder cancer (\n                      <jats:styled-content style=\"fixed-case\">NMIBC<\/jats:styled-content>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>\n                      A decision tree model was built based on European Association of Urology guidelines for the treatment and management of\n                      <jats:styled-content style=\"fixed-case\">NMIBC<\/jats:styled-content>\n                      . Input data were compiled from two recent studies comparing recurrence rates of bladder cancer in patients undergoing\n                      <jats:styled-content style=\"fixed-case\">TURBT<\/jats:styled-content>\n                      with either the current standard of care (\n                      <jats:styled-content style=\"fixed-case\">SOC<\/jats:styled-content>\n                      ) of white\u2010light cystoscopy, or with the\n                      <jats:styled-content style=\"fixed-case\">SOC<\/jats:styled-content>\n                      and\n                      <jats:styled-content style=\"fixed-case\">HAL<\/jats:styled-content>\n                      blue\u2010light cystoscopy. Using these published data with clinical cost data for surgical and outpatient procedures and pharmaceutical costs, the model reported on the clinical and economic differences associated with the two treatment options.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      This model demonstrates the significant clinical benefits likely to be observed through the incorporation of\n                      <jats:styled-content style=\"fixed-case\">HAL<\/jats:styled-content>\n                      blue\u2010light cystoscopy for\n                      <jats:styled-content style=\"fixed-case\">TURBT<\/jats:styled-content>\n                      in terms of reductions in recurrences of bladder cancer. Analysis of economic outputs of the model found that the use of one instillation of\n                      <jats:styled-content style=\"fixed-case\">HAL<\/jats:styled-content>\n                      for\n                      <jats:styled-content style=\"fixed-case\">TURBT<\/jats:styled-content>\n                      in all Swedish patients with\n                      <jats:styled-content style=\"fixed-case\">NMIBC<\/jats:styled-content>\n                      is likely to be cost\u2010neutral or cost\u2010saving over 5\u00a0years relative to the current\n                      <jats:styled-content style=\"fixed-case\">SOC<\/jats:styled-content>\n                      of white\u2010light cystoscopy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      The results of this analysis provide additional health economic rationale for the incorporation of a single instillation of\n                      <jats:styled-content style=\"fixed-case\">HAL<\/jats:styled-content>\n                      blue\u2010light cystoscopy for\n                      <jats:styled-content style=\"fixed-case\">TURBT<\/jats:styled-content>\n                      in the treatment of patients with\n                      <jats:styled-content style=\"fixed-case\">NMIBC<\/jats:styled-content>\n                      in Sweden.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bju.13261","type":"journal-article","created":{"date-parts":[[2015,8,25]],"date-time":"2015-08-25T11:39:46Z","timestamp":1440502786000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Budget impact of incorporating one instillation of hexaminolevulinate hydrochloride blue\u2010light cytoscopy in transurethral bladder tumour resection for patients with non\u2010muscle\u2010invasive bladder cancer in Sweden"],"prefix":"10.1111","volume":"117","author":[{"given":"James B.","family":"Rose","sequence":"first","affiliation":[{"name":"GfK Pera Business Park Melton Mowbray UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon","family":"Armstrong","sequence":"additional","affiliation":[{"name":"GfK Wayland MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregers G.","family":"Hermann","sequence":"additional","affiliation":[{"name":"Department of Urology University Hospital of Copenhagen Frederiksberg Hospital Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakob","family":"Kjellberg","sequence":"additional","affiliation":[{"name":"Danish Institute for Local and Regional Government Research (KORA) Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per\u2010Uno","family":"Malmstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences Uppsala University Akademiska Sjukhuset Uppsala Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,10,29]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.11.039"},{"key":"e_1_2_7_3_1","unstructured":"FerlayJ SoerjomataramI ErvikMet\u00a0al.GLOBOCAN 2012 v1.0 Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. International Agency for Research on Cancer;2013"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2012.11454.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-009-0395-z"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03262330"},{"key":"e_1_2_7_7_1","unstructured":"BabjukM B\u00f6hleA BurgerMet\u00a0al.EAU Guidelines on Non\u2010Muscle\u2010Bladder Cancer"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.07.062"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2014.130"},{"key":"e_1_2_7_10_1","first-page":"1","article-title":"Local recurrence and progression of non\u2010muscle\u2010invasive bladder cancer in Sweden : a population\u2010based follow\u2010up study","volume":"1805","author":"Liedberg F","year":"2015","journal-title":"Scand J Urol"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)64273-5"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2011.10374.x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.01.006"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2005.05249.x"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2010.04.019"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)64833-1"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000070437.14275.e0"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0302-2838(02)00068-4"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365590902808541"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000100480.70769.0e"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.03.059"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000060782.52358.04"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.03.034"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.03.028"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2011.10090.x"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.06.148"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.03.007"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.06.003"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.03.023"},{"key":"e_1_2_7_30_1","unstructured":"Worldbank.Sweden [Internet].World Data.2013. Available at:http:\/\/data.worldbank.org\/country\/sweden"},{"key":"e_1_2_7_31_1","unstructured":"EngholmG FerlayJ ChristensenNet\u00a0al.NORDCAN: Cancer Incidence Mortality Prevalence and Survival in the Nordic Countries Version 7.0 (17.12.2014). Association of the Nordic Cancer Registries. Danish Cancer Society [Internet]. Nordcan. 2014. Available at:http:\/\/www-dep.iarc.fr\/NORDCAN\/english\/frame.asp"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/jhh.2010.36"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2014.09.015"},{"key":"e_1_2_7_34_1","unstructured":"MiddletonMR.Sensit [Internet].2014. Available at:www.treeplan.com"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.06.037"},{"key":"e_1_2_7_36_1","unstructured":"Regionala Cancercentrum I Samverkan.Cancer i urinbl\u00e5sa urinledare och urinr\u00f6r \u2013 Nationallt vardprogram"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12355"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.3109\/21681805.2015.1019562"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2014.02.857"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0096849"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2004.09.050"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOU.0000000000000078"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2015.12"},{"key":"e_1_2_7_44_1","unstructured":"Sk\u00e5nelistan.Sk\u00e5nelistan: Rekommenderade l\u00e4kemedel. L\u00e4kemedelsr\u00e5det i Region Sk\u00e5ne. [Internet]. Available at:https:\/\/www.skane.se\/lakemedelsradet\/skanelistan"},{"key":"e_1_2_7_45_1","unstructured":"Socialstyrelsen.NordDRG. [Internet]. (2014). Available at:http:\/\/www.socialstyrelsen.se\/klassificeringochkoder\/norddrg"},{"key":"e_1_2_7_46_1","unstructured":"Apoteket. Hexvix [Internet]. (2015). Available at:https:\/\/www.apoteket.se\/produkt\/hexvix-pulver-och-vatska-till-intravesikal-anvandning-losning-85-mg-1-st-inj-fl-214861\/"},{"key":"e_1_2_7_47_1","unstructured":"TLV.Ans\u00f6k om pris eller subvention [Internet]. Dent. Pharm. Benefits Agency.2014. Available at:http:\/\/www.tlv.se\/"},{"key":"e_1_2_7_48_1","unstructured":"Sk\u00e5nelistan.Bild\u2010och funktionsmedicin prislista 2014 Region Sk\u00e5ne [Internet]. Available at:http:\/\/www.skane.se\/Upload\/Webbplatser\/Skaneportalen-extern\/VardHalsa\/Uppdrag2014\/2PrislistaBFM2014.pdf"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbju.13261","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbju.13261","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.13261","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:25:49Z","timestamp":1761740749000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.13261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,29]]},"references-count":47,"journal-issue":{"issue":"6B","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.1111\/bju.13261"],"URL":"https:\/\/doi.org\/10.1111\/bju.13261","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,29]]},"assertion":[{"value":"2015-10-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}